Clinical and MSUS guided anti-TNF reduction in RA

Full Title:

Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-TNF therapy?

Authors:

Dr Jonathan L Marks MB BS MRCP\(^1,2\)*; Dr Christopher R Holroyd BM MRCP\(^2\)*; Dr Borislav D Dimitrov, MD DM PhD \(^3\); Dr Ray D Armstrong\(^2\); Dr Antonia Calogeras\(^2\); Prof Cyrus Cooper\(^2,4,5,6\); Dr Brian K Davidson\(^2\); Prof Elaine M Dennison\(^2,4\); Dr Nicholas C Harvey\(^2,4,5\); Dr Christopher J Edwards MD FRCP \(^1,2,4,6\).

*JLM and CRH are joint first authors

1. NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton, United Kingdom
2. Department of Rheumatology, University Hospital Southampton, Southampton, United Kingdom
3. Primary Care and Population Sciences, University of Southampton, Southampton, United Kingdom
4. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
5. NIHR Southampton biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
6. NHIR Musculoskeletal Biomedical Research Unity, University of Oxford, Oxford, UK

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi: 10.1002/acr.22552

© 2015 American College of Rheumatology

Received: Jul 22, 2014; Revised: Dec 03, 2014; Accepted: Jan 13, 2015

This article is protected by copyright. All rights reserved.
Corresponding Author:

Dr Christopher J Edwards

Department of Rheumatology, University Hospital Southampton, Southampton, Hampshire, United Kingdom

Tel: +44 23 8079 6452

Fax: +44 23 8079 6965

Email: cedwards@soton.ac.uk

Declaration of Financial Interests:

CRH has received speaking fees from Abbvie, MSD, UCB, and BMS

CJE has received grant support, provided consultancy and been on the speakers bureau for Pfizer, AbbVie, MSD, Roche, UCB, Celgene, Samsung Bioepis, Jansen and BMS

CC has received consultancy, lecture fees and honoraria from AMGEN, GSK, Alliance for Better Bone Health, MSD, Eli Lilly, Pfizer, Novartis, Servier, Merck, Medtronic and Roche

EMD has received speakers fees from Lilly

JLM has received honorarium from AbbVie

All other authors have no financial interests to declare

Word Count: 2776
Abstract

Objectives: To investigate if a strategy combining clinical and ultrasound (US) assessment can select individuals with rheumatoid arthritis (RA) for sustained dose reduction of anti-tumor necrosis factor (TNF) therapies.

Methods: As part of a real-world approach, patients with RA receiving anti-TNF therapies were reviewed in a dedicated biologics clinic. Patients not taking oral corticosteroids with both DAS28 remission (≤2.6) and absent synovitis on power doppler US (PDUS=0) for more than 6 months were invited to reduce their anti-TNF therapy dose by one third.

Results: Between January 2012 and February 2014, a total of 70 patients underwent anti-TNF dose reduction. Combined DAS28 and PDUS remission was maintained by 96% at 3 months, 63% at 6 months, 37% at 9 months and 34% at 18 months follow-up. However, 88% of patients maintained at least low disease activity (LDA) with DAS28 <3.2 and PDUS ≤1 at 6 months. The addition of PDUS identified 8 patients (25% of those that flared), in DAS28 remission, with sub-clinically active disease. Those who maintained dose reduction were more likely to be rheumatoid factor (RF) negative (46% versus 17%; p=0.03) and have lower DAS-28 scores at biologic initiation (5.58 versus 5.96; p=0.038).

Conclusions: Combined clinical and US assessment identifies individuals in remission who may be suitable for anti-TNF dose reduction and enhances safe monitoring for sub-clinical disease flares. Despite long-standing severe RA, a sub-set of our cohort sustained prolonged DAS28 and PDUS remission. Lower disease activity at biologic therapy initiation and RF status appeared predictive of sustained remission.
Significance and Innovations

- First description of a real-world anti-TNF reduction strategy in patients with severe, chronic RA

- It may be possible to use a strategy of combined clinical and ultrasound assessments to identify patients in remission suitable for anti-TNF dose reduction
In the treatment of rheumatoid arthritis (RA), biologic therapies including tumor necrosis factor inhibitors (anti-TNF) reduce disease activity\(^1\)\(^-\)\(^3\), preserve physical function and prevent joint damage and consequent disability\(^4\)\(^-\)\(^7\). Current guidelines for the management of RA propose rapid escalation of drug treatment to control disease activity\(^8\),\(^9\). This approach encourages the early use of combination disease-modifying anti-rheumatic drug (DMARD) therapy and the addition of biologic therapies for patients with poor prognostic signs or for those that fail to achieve prompt disease control with conventional DMARDs.

Despite the clinical efficacy of anti-TNF therapies and a generally reassuring safety profile, some concerns remain regarding their long-term use due to the increased incidence of serious infections, tuberculosis\(^10\),\(^11\) and potential malignancies\(^12\). The cost of anti-TNF therapy is also an important consideration and leads to restrictions on prescribing in many countries\(^13\). These combined factors have encouraged the investigation of the potential for anti-TNF dose reduction or discontinuation strategies for patients achieving clinical remission or low disease activity (LDA)\(^14\)\(^-\)\(^16\).

Evidence to date suggests that while anti-TNF therapy may be discontinued, at least in the short to medium term for some patients treated early in their disease course\(^17\), stopping anti-TNF in established disease leads to high rates of relapse\(^16\). For this reason it has been suggested that in established disease, dose reduction may be a more realistic approach and can be considered for patients in remission or LDA, either by increasing the interval between doses or reducing the dose administered\(^9\),\(^18\).
Means of accurately assessing disease activity are vital if anti-TNF therapy is going to be reduced. Clinical measures of remission alone, such as the DAS-28 assessment, may underestimate the degree of synovitis with the consequence that joint damage continues to accrue. One way of addressing this concern is by using imaging technology such as ultrasound (US) or magnetic resonance imaging (MRI). Previous studies have demonstrated that ongoing synovitis can be detected by US in up to 62% of patients in clinical remission\textsuperscript{19-21} and that synovitis demonstrated by power doppler ultrasound (PDUS) correlates with both progression of structural damage\textsuperscript{22} and risk of subsequent RA flare\textsuperscript{23}. As a result the use of US assessment for patients in clinical remission has been proposed\textsuperscript{24}.

To explore this further we implemented a combined clinical and US assessment program as part of real-world care for patients receiving biologic therapies for RA. These combined assessments were then used to define individuals in both clinical and US remission as part of a strategy to select the most appropriate patients for dose reduction.

**Patients and Methods**

Ethical approval to report anonymised routine clinical data for the study was not required by the National Health Research Authority. However, our local Biologic Therapy Steering Group assessed progress and ensured the study was carried out to international standards of Good Clinical Practice (GCP).
As a pragmatic approach to achieving the best clinical outcomes we developed a dedicated clinic for patients with inflammatory arthritis receiving biologic therapy who were identified from within the existing departmental cohort and channeled into the new service. Hospital records were examined from diagnosis onwards and relevant characteristics entered into a biologics database. Patients all received standard care within the United Kingdom (UK) National Health Service (NHS). This provides comprehensive healthcare to all UK citizens free at the point of delivery and is funded from general taxation. In the UK, to be eligible for anti-TNF therapy, patients must meet National Institute for Health and Care Excellence (NICE) criteria: DAS-28 score >5.1 on two occasions at least 1 month apart despite treatment with at least two DMARDs - one of which must be methotrexate.13

All patients attending the clinic underwent regular clinical examination (including DAS-28 assessment) by the same consultant or specialist nurse. In addition, patients underwent standardised PDUS imaging of their hands and wrists (Esoate Mylab 70, Esoate, Genova, Italy. Esaote Linear probe: LA435 (40mm, frequency setting 18 mHz for wrist, MCPJs and PIPJs); Mechanical Index: 0.65; PRF settings: Usual PRF set at 750 Hz (possible range 125 Hz - 21.9 kHz)) by either a consultant rheumatologist or trained musculoskeletal ultrasonographer. A total of 18 joints were scanned, consisting of MCPJ 2-5, PIPJ 2-5 (dorsal midline longitudinal view) and wrists (3 dorsal longitudinal views: midline (radio-lunate-capitate), medial (radio-carpal) and lateral (distal ulnar-carpal) bilaterally. PDUS findings were graded on a 0-3 semi-quantitative scale where 0 indicated no vascularity and 3 indicated marked hyperaemia in line with previously proposed scales.25,26
operator variability (IOV) demonstrated substantial agreement (Kappa statistic = 0.7545 SE 0.088 (95% CI=0.58-0.93) between ultrasonographers.

From January 2012, all patients receiving a biologic therapy were routinely reviewed 12 weeks after initiating therapy and then every 24 weeks in the biologics clinic. Dose reduction of anti-TNF was discussed with patients if they had been receiving anti-TNF therapy for more than a year, were not taking oral corticosteroids and were in DAS-28 remission (<2.6) for more than six months with no evidence of synovitis on PDUS. A one-third reduction was proposed (Adalimumab 40mg every 3 weeks; Etanercept 50mg every 10 days; Infliximab 2mg/kg per infusion; Certolizumab 200mg every 3 weeks; Golimumab 50mg every 6 weeks) with follow up at 12 weeks and then every 24 weeks thereafter. Patients who did not meet these criteria, or elected not to undergo dose reduction, continued with routine 24-week follow-up (Figure 1). All patients were advised to telephone a dedicated specialist nurse helpline if they felt their disease control deteriorated prior to the next planned consultation. All patients who telephoned the helpline were reviewed within 2 working days. Following dose reduction, treatment failure was defined as either loss of DAS28 remission (DAS28 ≥2.6), evidence of synovitis on PDUS (score ≥1) in any joint or disease recurrence as defined by the patient. Patients who flared were re-escalated to full treatment dose.

Statistical Methods

All continuous variables were checked for normality of the distributions. Differences in the baseline characteristics between patients undergoing dose reduction and
those continuing on standard dose anti-TNF were assessed for statistical significance using chi-squared test, Fisher’s exact tests, t-test or Mann-Whitney test or as appropriate, with a p≤0.05 considered as being statistically significant. In the patients who underwent anti-TNF dose reduction, univariate and multivariate regression analyses were performed to investigate factors influencing sustained remission. Multivariate analysis included adjustment for age, sex, ethnicity, rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA) status, duration of disease prior to anti-TNF therapy and duration of treatment with anti-TNF prior to achieving remission. All analyses were performed with the statistical software SPSS ver.21 (IBM Corporation, USA).

Results

Between 1st January 2012 and 4th February 2014, 321 patients with RA (ACR-EULAR 2010 criteria) were treated with a biologic, of whom 219 were receiving anti-TNF therapies. Patients had long-standing (mean 10.54 years), severe RA (mean DAS-28: 5.75 on initiation of anti-TNF) and had generally failed multiple DMARDs prior to biologic initiation (mean 3.6 DMARDs) (Table 1).

A total of 115 patients (36%) met eligibility criteria for anti-TNF dose reduction, of whom 70 patients agreed to undergo dose reduction. One patient was excluded from our analysis due to missing data. Older patients were more likely to agree to undertake anti-TNF reduction [mean (SD) age 61.86 (12.81) versus 57.74 (14.06) years, p=0.039].
To understand what factors might predict sustained dose reduction we first performed a cross-sectional analysis of our cohort. This demonstrated that 37 patients (54%) who underwent anti-TNF dose reduction had remained in sustained DAS28 and PDUS remission at an average of 10.2 months (SD 6.52) follow-up. 32 patients (46%) had flared with this occurring typically between months 3 and 9 (mean time to flare 7.65 months; SD 5.17).

Sustained remission was more likely in patients with a lower DAS-28 at anti-TNF initiation [5.58 (SD 0.72) versus 5.96 (SD 0.85), p=0.04] and also in patients who were RF negative [44.1% versus 16.7%, p=0.03] (Table 2). There were no other significant differences in measured baseline characteristics between the two groups and no differences in the component parts of the DAS28 score (tender joint count; swollen joint count; VAS score or ESR). Using logistic regression modeling, lower DAS-28 at anti-TNF initiation was associated with a significantly greater probability of sustained dose reduction [OR = 2.04; 95%CI 1.006 to 4.133, p=0.048]. No other statistically significant associations were identified.

To further analyze how and when patients flared we then examined individual case data. This demonstrated that following dose reduction 96% maintained combined DAS28 (<2.6) and PDUS remission (PDUS=0) at 3 months, 63% at 6 months, 37% at 9 months and 34% after 18 months follow-up. However, 88% of patients maintained at least low disease activity (LDA) with DAS28 <3.2 and PDUS ≤1 at 6 months. In patients who maintained remission beyond 9 months, this appeared to be largely
sustained with only 2 further drop-outs due to disease flare by 18 months follow up (Figure 2).

Of the patients who failed to maintain remission on a reduced dose of anti-TNF, 41% demonstrated an increase in DAS28 score only, 25% demonstrated development of synovitis using PDUS only and 25% demonstrated both an increased DAS28 and PDUS activity. Mean change in DAS28 was +1.14 (SD 1.02) for those patients demonstrating increased clinical disease activity. Using an increase in DAS28 of >1.2 to define a flare of RA, only 34% of patients in our cohort would have been classified as flaring following dose reduction though half of these patients also demonstrated PDUS at the time of re-escalation. Three patients (9%) felt as if they had flared following dose reduction despite maintaining DAS28 and PDUS defined measures of remission.

Following disease flare and treatment re-escalation 6 patients (19%) returned to combined DAS28 and PDUS remission, 6 (19%) patients were in DAS28 remission (with active synovitis on PDUS assessment) and 15 patients (47%) demonstrated LDA (DAS ≥2.6 to <3.2). Five patients (15%) had moderate disease activity (DAS28 ≥3.2 to <5.1) despite re-escalation of treatment after an average 15 months further follow-up. No patients had severe disease activity (DAS28 ≥ 5.1) or required a change of biologic treatment following anti-TNF dose reduction.

Discussion
Using clinical and US criteria to define remission in a group of patients with severe longstanding RA we have shown that at 6 months following dose reduction 63% remained in a stringent remission criteria of DAS28<2.6 and PDUS=0. It is also worth pointing out that 88% of patients maintained at least low disease activity (LDA) with DAS28 <3.2 and PDUS ≤1 at 6 months. However, longer-term follow-up suggests that by 18 months around two thirds of patients had flared. Interestingly, flares appeared to occur predominantly between months 3 and 9 after dose reduction. Further flare was rare after this time point suggesting that patients declare their “flare phenotype” early. In addition, certain characteristics such as being RF negative and having a lower DAS28 at anti-TNF initiation seemed to reduce the likelihood of flare, though the difference in mean DAS28 between the two groups was small (0.38) and less than measurement error for DAS28 (0.6)\(^ {28}\). Our results suggest that it may be possible to identify individuals who are most appropriate for dose reduction using a combination of biomarkers (including PDUS assessment) and clinical scoring systems.

This study has several advantages. It is the first to report the outcomes of anti-TNF dose reduction as part of real-world clinical practice. While other studies have demonstrated the value of US assessment when making decisions about escalating treatment\(^ {29,30}\), this study is unique in including the US assessment of synovitis as part of the clinical decision-making algorithm when tapering biologic therapy. Because of the uncertainties that still exist when integrating US into clinical decision making, and because our patients had severe longstanding disease, we adopted a cautious approach defining US remission as PDUS =0 in all joints, even though the significance
of grade 1 change is uncertain and can occur in patients with osteoarthritis \(^{31}\) and a proportion of healthy volunteers \(^{32}\). We elected to make treatment decisions on the basis of PDUS only and ignored grayscale changes because their significance in later RA remains uncertain\(^ {33}\). Following anti-TNF dose reduction 8 patients were identified as having sub-clinical synovitis despite DAS28 remission using US at routine follow-up appointments. In 4 of these patients PDUS was only grade 1 (in at least two joints), and in the remaining 4 PDUS was >1 (in at least two joints).

We ensured that patients were involved in a shared decision-making process when considering their dose reduction. We chose a dose reduction of one third primarily because of concerns regarding disease flare following reduction in a cohort of patients with such long-standing severe disease. In addition, this was a real-world clinical situation, and our policy of shared-care decision-making meant that we felt patients were unlikely to agree to a voluntary 50% reduction outside of a more formal clinical trial. Even with this cautious approach it is interesting to note that of patients who appeared clinically eligible for anti-TNF reduction a significant proportion (40%) elected not to take part. This group were younger [55.75 years (SD 16.04) versus 61.86 years (SD 12.81), \(p=0.01\)] but were otherwise well matched with those that underwent dose reduction. The age differential may reflect younger patients concerns regarding the loss of remission state and its impact on quality of life and work participation.

Other recent studies have explored the possibility of dose reduction. Compared to our results, the PRESERVE (Prospective, Randomized Etanercept Study to Evaluate
Reduced dose Etanercept combined with MTX versus full dose Etanercept combined with MTX versus MTX alone) trial 16, reported that 60.2% of patients maintained DAS28 remission (<2.6) following a 50% reduction in the dose of etanercept at 9 months follow-up. However, our population had significantly longer disease duration (mean 10.5 years versus 6.3 years) and higher disease activity (mean baseline DAS 5.75 versus 4.4) compared to the PRESERVE participants.

Our data suggests that lower DAS28 at biologic initiation and being RF negative may be predictive of the likely success of anti-TNF dose reduction. The results of ongoing trials such as PRIZE (Productivity and Remission in a Randomized Controlled Trial of etanercept versus Standard of Care in Early Rheumatoid Arthritis) 34 and DOSERA (Discontinuing Etanercept in Subjects With Rheumatoid Arthritis) 35 should provide further clarity regarding the suitability of dose reduction for patients with either very early, or very late RA respectively.

There is uncertainty regarding the long-term prospects for maintaining remission on reduced dose biologics. Our results suggest that in long-standing RA, the majority of patients will experience disease flare, though it is reassuring that 85% of those who flare will re-attain LDA or remission following return to standard dose anti-TNF therapy. Real-world studies such as this can provide important long-term follow up data to inform future decision-making. While dose reduction may be possible within the context of time-limited clinical trials, the practicality of translating such clinical trial data to everyday practice over the longer term remains to be established.
There are a number of limitations to our study. Firstly, US is well recognized as being subject to user variability. We used either a single trained consultant rheumatologist or a single trained MSK ultrasonographer who both perform scans routinely in the clinic with good IOV. While our US room is temperature controlled, we did not control for other factors that may influence the detection of synovitis by PDUS, such as concomitant NSAIDs use, joint position, alcohol or caffeine consumption or recent physical exertion. For pragmatic reasons we did not use a validated US scoring system such as the 12-joint or 7-joint count nor did we assess foot synovitis. Therefore we may have under-estimated the overall likelihood of disease remission though we would have expected patients with active arthritis in non-assessed joints to decline dose reduction. Finally, because the criteria that we applied to define successful dose reduction are stricter than current EULAR targets of LDA or remission, this introduces the possibility that we over-identified disease flare. Consequently, our data may well underestimate the true value of dose reduction.

Conclusions

Anti-TNF dose reduction by one third is possible for some patients with severe long-standing RA and can be undertaken safely within the confines of routine clinical practice. The use of semi-quantitative PDUS scoring in addition to clinical assessment and disease characteristics may enable clinicians to identify and safely monitor individuals in whom this can be considered.
References


6. van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and
their correlations with clinical and radiographic measures from a randomized controlled trial companion study. *Arthritis care & research.* Feb 2010;62(2):226-234.


23. Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli G. Clinical and ultrasonographic remission determines different chances of relapse in


35. van Vollenhoven RV F-LK. In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept at 50mg or 25mg weekly are both clinically superior to discontinuation: results from a randomized, 3-arm, double-blind study. *Ann Rheumatic Dis*. 2013;72(3):434.


Figure 1 – Schematic for patient pathway

Figure 1 - Schematic for Patient Pathway
254x190mm (72 x 72 DPI)
Figure 2 – Percentage of individuals maintaining sustained DAS28 and PDUS remission following dose reduction by time

254x190mm (72 x 72 DPI)
Examples of Grade I to III Power Doppler Ultrasound (PDUS) signal

254x190mm (96 x 96 DPI)
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Non-reducers</th>
<th>Dose Reducers</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects, N</td>
<td>149</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>Female Sex, N (%)</td>
<td>162 (74.0)</td>
<td>52 (74.3)</td>
<td>0.942</td>
</tr>
<tr>
<td>Age, years</td>
<td>57.74 ± 14.06</td>
<td>61.86 ± 12.81</td>
<td>0.039</td>
</tr>
<tr>
<td>Caucasian (%)</td>
<td>139 (93.3)</td>
<td>65 (92.9)</td>
<td>0.906</td>
</tr>
<tr>
<td>Current Smoker (%)</td>
<td>24 (18.5)</td>
<td>7 (10.1)</td>
<td>0.305</td>
</tr>
<tr>
<td>RhF positive, (%)</td>
<td>97 (70.3)</td>
<td>45 (69.2)</td>
<td>0.878</td>
</tr>
<tr>
<td>ACPA positive, (%)</td>
<td>57 (71.3)</td>
<td>24 (68.6)</td>
<td>0.772</td>
</tr>
<tr>
<td>Disease duration until first biologic (months)</td>
<td>125.5 ± 100.7</td>
<td>129.5 ± 119.0</td>
<td>0.092</td>
</tr>
<tr>
<td>DMARDs prior to biologic, N</td>
<td>3.60 ±2.05</td>
<td>3.57 ±1.85</td>
<td>0.212</td>
</tr>
<tr>
<td>DAS28 Score prior to biologic initiation</td>
<td>5.66 ±0.99</td>
<td>5.75 ±0.83</td>
<td>0.287</td>
</tr>
<tr>
<td>DMARD co-prescribed with anti-TNF (%)</td>
<td>122 (81.88)</td>
<td>59 (84.29)</td>
<td>0.069</td>
</tr>
</tbody>
</table>

*Values are mean ± SD unless otherwise indicated. RhF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; DMARD = disease-modifying anti-rheumatic drug; DAS28 = Disease Activity Score in 28 joints.
Table 2 - Characteristics of sustained and non-sustained anti-TNF reducers *

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Sustained</th>
<th>Non-Sustained</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects, N</td>
<td>37</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Female Sex, N (%)</td>
<td>24 (64.9)</td>
<td>27 (84.4)</td>
<td>0.066</td>
</tr>
<tr>
<td>Age, (years)</td>
<td>60.57 ± 12.37</td>
<td>64.5 ± 11.72</td>
<td>0.065</td>
</tr>
<tr>
<td>Caucasian (%)</td>
<td>35 (94.6)</td>
<td>29 (90.6)</td>
<td>0.526</td>
</tr>
<tr>
<td>Current Smoker (%)</td>
<td>4 (10.8)</td>
<td>3 (9.7)</td>
<td>0.988</td>
</tr>
<tr>
<td>RhF positive, (%)</td>
<td>19 (55.9)</td>
<td>25 (83.3)</td>
<td>0.030</td>
</tr>
<tr>
<td>ACPA positive, (%)</td>
<td>12 (60)</td>
<td>12 (80.0)</td>
<td>0.281</td>
</tr>
<tr>
<td>Disease duration until first biologic, (months)</td>
<td>123.1 ± 111.7</td>
<td>141.7 ± 123.1</td>
<td>0.313</td>
</tr>
<tr>
<td>DMARDs prior to biologic, N</td>
<td>3.64 ± 1.79</td>
<td>3.39 ± 1.66</td>
<td>0.693</td>
</tr>
<tr>
<td>DAS28 Score prior to biologic initiation</td>
<td>5.58 ± 0.72</td>
<td>5.96 ± 0.85</td>
<td>0.040</td>
</tr>
<tr>
<td>DMARD co-prescribed with anti-TNF (%)</td>
<td>33 (89.2)</td>
<td>25 (78.1)</td>
<td>0.452</td>
</tr>
</tbody>
</table>

* Values are mean ± SD unless otherwise indicated. RhF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; DMARD = disease-modifying anti-rheumatic drug; DAS28 = Disease Activity Score in 28 joints.